Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN - Get Free Report) have been given an average rating of "Moderate Buy" by the six analysts that are presently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokers that have covered the stock in the last year is $4.25.

Several brokerages have recently commented on MRSN. Wedbush restated an "outperform" rating and issued a $4.00 target price on shares of Mersana Therapeutics in a research note on Monday, March 3rd. Citigroup assumed coverage on Mersana Therapeutics in a report on Friday, November 15th. They issued a "buy" rating and a $5.00 price target for the company. Finally, William Blair assumed coverage on Mersana Therapeutics in a report on Thursday, February 6th. They issued an "outperform" rating for the company.

Institutional Trading of Mersana Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. US Bancorp DE bought a new stake in Mersana Therapeutics during the 3rd quarter worth about $31,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Mersana Therapeutics in the 3rd quarter valued at approximately $34,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Mersana Therapeutics in the 4th quarter valued at approximately $37,000. Intech Investment Management LLC acquired a new position in shares of Mersana Therapeutics in the 3rd quarter valued at approximately $52,000. Finally, Quarry LP acquired a new position in shares of Mersana Therapeutics in the 3rd quarter valued at approximately $57,000. 93.92% of the stock is owned by institutional investors.

Mersana Therapeutics Stock Up 5.7 %

Shares of NASDAQ:MRSN opened at $0.51 on Thursday. Mersana Therapeutics has a 52 week low of $0.45 and a 52 week high of $5.96. The company has a debt-to-equity ratio of 13.35, a quick ratio of 2.35 and a current ratio of 2.35. The company's fifty day moving average is $0.70 and its 200-day moving average is $1.53. The company has a market capitalization of $63.60 million, a PE ratio of -0.84 and a beta of 1.67.

Remove Ads

Mersana Therapeutics (NASDAQ:MRSN - Get Free Report) last issued its earnings results on Monday, March 3rd. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.05. Mersana Therapeutics had a negative net margin of 214.20% and a negative return on equity of 401.37%. The company had revenue of $16.36 million for the quarter, compared to the consensus estimate of $7.71 million. Equities research analysts predict that Mersana Therapeutics will post -0.62 earnings per share for the current fiscal year.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.